Anna Petrovna Men'SHenina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Petrovna Men'SHenina has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Elena Mikhaylovna Frantsiyants
National Medical Research Center of Oncology, Ministry of Health of Russia
23 shared publications - Ekaterina V. Verenikina
National Medical Research Centre for Oncology
18 shared publications - Irina Valer'EVna Neskubina
National Medical Research Center of Oncology, Ministry of Health of Russia
17 shared publications - Valeriya Akhtyamovna Bandovkina
National Medical Research Center of Oncology, Ministry of Health of Russia
17 shared publications - Ekaterina Igorevna Surikova
National Medical Research Centre for Oncology Rostov-on-Don, Russian Federation
15 shared publications - Alla Ivanovna Shikhlyarova
National Medical Research Center of Oncology, Ministry of Health of Russia
12 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (3) , 49-66
Morphological characteristics of An3Ca endometrioid carcinoma and visceral organs in female nude mice with experimental diabetes mellitus
Purpose of the study . To investigate the morphological features of induced An3Ca endometrioid carcinoma and visceral organs in BALB/c nude mice under conditions of diabetes mellitus. Materials and methods . Female BALB/c nude mice weighing 25 ± 2.5 g were used to model uterine tumor growth under conditions of diabetes mellitus. The animals were divided into two experimental groups: group 1 (control) – intrauterine growth of endometrioid carcinoma (n = 5); group 2 (study group) – intrauterine growth of endometrioid carcinoma in the presence of diabetes mellitus (n = 5). Sections of the tumor nodules and organs (uterus, ovaries, liver, lungs, thyroid gland, adrenal glands, and pancreas) were examined microscopically, with images captured using a digital camera. Results . Tumor growth without alloxan administration resulted in the formation of a single tumor nodule in the right uterine horn, with preservation of the main morphological features of its architecture. In contrast, alloxan administration was associated with the formation of a tumor consisting of several separate nodules that completely obliterated the structure of the right ovary and replaced it with tumor tissue. Metastatic involvement of the liver accompanied by vascular congestion of the parenchyma was observed. In the lungs, destruction of the alveolar and bronchial structures was accompanied by vascular congestion, foci of hemorrhage, mucus accumulation in the airway lumens, and the presence of tumor cells. Marked thickening of the colloid was observed throughout the thyroid follicles. Involutional changes were noted in the X-zone and zona glomerulosa of the adrenal cortex, with focal expansion of the zona fasciculata. Diabetes modeling resulted in almost complete loss of the exocrine pancreatic parenchyma, exposing the stromal framework of the organ. Its morphological identity could be established only from isolated small areas of degeneratively altered acini and rare remnants of the islets of Langerhans. Conclusion . In the experimental bimodal model combining two pathological processes, cancer and diabetes mellitus, morphological evidence of mutually reinforcing mechanisms of adverse systemic effects involving multiple organs was observed. This pronounced synergistic effect was manifested by stimulation of tumor progression and pathological changes in visceral organs, expanding our understanding of cancer pathogenesis in the presence of comorbid disease.
- 20 September 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (3) , 49-66
Open AccessMorphological characteristics of An3Ca endometrioid carcinoma and visceral organs in female nude mice with experimental diabetes mellitus
Purpose of the study . To investigate the morphological features of induced An3Ca endometrioid carcinoma and visceral organs in BALB/c nude mice under conditions of diabetes mellitus. Materials and methods . Female BALB/c nude mice weighing 25 ± 2.5 g were used to model uterine tumor growth under conditions of diabetes mellitus. The animals were divided into two experimental groups: group 1 (control) – intrauterine growth of endometrioid carcinoma (n = 5); group 2 (study group) – intrauterine growth of endometrioid carcinoma in the presence of diabetes mellitus (n = 5). Sections of the tumor nodules and organs (uterus, ovaries, liver, lungs, thyroid gland, adrenal glands, and pancreas) were examined microscopically, with images captured using a digital camera. Results . Tumor growth without alloxan administration resulted in the formation of a single tumor nodule in the right uterine horn, with preservation of the main morphological features of its architecture. In contrast, alloxan administration was associated with the formation of a tumor consisting of several separate nodules that completely obliterated the structure of the right ovary and replaced it with tumor tissue. Metastatic involvement of the liver accompanied by vascular congestion of the parenchyma was observed. In the lungs, destruction of the alveolar and bronchial structures was accompanied by vascular congestion, foci of hemorrhage, mucus accumulation in the airway lumens, and the presence of tumor cells. Marked thickening of the colloid was observed throughout the thyroid follicles. Involutional changes were noted in the X-zone and zona glomerulosa of the adrenal cortex, with focal expansion of the zona fasciculata. Diabetes modeling resulted in almost complete loss of the exocrine pancreatic parenchyma, exposing the stromal framework of the organ. Its morphological identity could be established only from isolated small areas of degeneratively altered acini and rare remnants of the islets of Langerhans. Conclusion . In the experimental bimodal model combining two pathological processes, cancer and diabetes mellitus, morphological evidence of mutually reinforcing mechanisms of adverse systemic effects involving multiple organs was observed. This pronounced synergistic effect was manifested by stimulation of tumor progression and pathological changes in visceral organs, expanding our understanding of cancer pathogenesis in the presence of comorbid disease.
- Open Access
- 18 September 2026
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 13 (3) , 8-19
The genes copy number variation features in blood plasma of uterine cancer patients and disease prognosis
Introduction. Uterine cancer is a leading gynecologic oncology morbidity. Early prediction of metastatic disease is critical for treatment decisions. Therefore, the search for minimally invasive molecular markers for predicting metastasis is a pressing issue. Promising biomarkers in this regard include gene copy number values in circulating cell-free DNA (cfDNA) in plasma. Aim. To analyze the relative copy number of genes regulating mitochondrial function in plasma of uterine cancer patients to develop a minimally invasive method for predicting metastasis. Materials and methods. The bioinformatics phase of the study identified a list of genes associated with mitochondrial dysfunction and abnormal copy number in uterine cancer. The study included 98 patients diagnosed with adenocarcinoma of the corpus uteri (G1 (n = 43), G2 (n = 35) and G3 (n = 20)), 15 patients with uterine myoma and 20 conditionally healthy donors. The relative copy number of 13 genes was determined by quantitative real-time polymerase chain reaction on cfDNA samples from blood plasma. ROC analysis and LASSO-penalized (LASSO – Least Absolute Shrinkage and Selection Operator) logistic regression were used to select markers. Results. A significant decrease in relative copy number of mtSSB, MT-RNR2, NRF1, MGME1, and MT-CO1 in plasma was revealed in uterine cancer patients (p 0.005) with a metastatic course of the disease, moreover, the degree of change in copy number increased from G1 to G3. LASSO regression analysis enabled the selection of three genes: mtSSB, MT-RNR2, and MGME1. The combined panel achieved an area under the curve (AUC) of 0.98 (95 % confidence interval 0.96–1.00), a sensitivity of 95 %, and a specificity of 92 % for predicting metastases. Conclusion. Thus, determination of the copy number of the mtSSB, MT-RNR2 and MGME1 genes in blood plasma has potential for use in minimally invasive prediction of metastatic lesions in uterine cancer.
- 18 September 2026
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 13 (3) , 8-19
Open AccessThe genes copy number variation features in blood plasma of uterine cancer patients and disease prognosis
Introduction. Uterine cancer is a leading gynecologic oncology morbidity. Early prediction of metastatic disease is critical for treatment decisions. Therefore, the search for minimally invasive molecular markers for predicting metastasis is a pressing issue. Promising biomarkers in this regard include gene copy number values in circulating cell-free DNA (cfDNA) in plasma. Aim. To analyze the relative copy number of genes regulating mitochondrial function in plasma of uterine cancer patients to develop a minimally invasive method for predicting metastasis. Materials and methods. The bioinformatics phase of the study identified a list of genes associated with mitochondrial dysfunction and abnormal copy number in uterine cancer. The study included 98 patients diagnosed with adenocarcinoma of the corpus uteri (G1 (n = 43), G2 (n = 35) and G3 (n = 20)), 15 patients with uterine myoma and 20 conditionally healthy donors. The relative copy number of 13 genes was determined by quantitative real-time polymerase chain reaction on cfDNA samples from blood plasma. ROC analysis and LASSO-penalized (LASSO – Least Absolute Shrinkage and Selection Operator) logistic regression were used to select markers. Results. A significant decrease in relative copy number of mtSSB, MT-RNR2, NRF1, MGME1, and MT-CO1 in plasma was revealed in uterine cancer patients (p 0.005) with a metastatic course of the disease, moreover, the degree of change in copy number increased from G1 to G3. LASSO regression analysis enabled the selection of three genes: mtSSB, MT-RNR2, and MGME1. The combined panel achieved an area under the curve (AUC) of 0.98 (95 % confidence interval 0.96–1.00), a sensitivity of 95 %, and a specificity of 92 % for predicting metastases. Conclusion. Thus, determination of the copy number of the mtSSB, MT-RNR2 and MGME1 genes in blood plasma has potential for use in minimally invasive prediction of metastatic lesions in uterine cancer.
- 23 June 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (2) , 34-46
Features of steroid hormone and receptor content in the mitochondria of endometrial adenocarcinoma according to tumor differentiation grade and the presence of type 2 diabetes mellitus
Mitochondria play a key role in cellular metabolism, steroid hormone synthesis, and the regulation of redox homeostasis. However, the role of mitochondrial steroidogenesis in the progression of endometrial adenocarcinoma (EA), particularly in the presence of type 2 diabetes mellitus (T2DM), remains poorly understood. Purpose of the study. To determine the concentrations of steroid hormones and their receptors in the mitochondrial fraction of G1–G3 endometrial adenocarcinoma tissue compared with intact endometrium and to evaluate the modifying effect of type 2 diabetes mellitus on these parameters. Patients and methods. Mitochondria were isolated by differential centrifugation from tumor tissue obtained from 92 patients with endometrial adenocarcinoma (G1–G3) and from morphologically normal endometrium (control group). Standard enzyme-linked immunosorbent assay (ELISA) kits were used to determine the concentrations of estradiol (E2), estriol (E3), estrone (E1) and their receptors (ERα, ERβ), testosterone (T) and the androgen receptor (AR), progesterone (P4) and the progesterone receptor (PR), as well as cortisol and cholesterol. Statistical analysis was performed using Statistica 10 software. Results. In the mitochondria of G1–G2 endometrial adenocarcinomas, the estradiol level was approximately twofold higher than in the control group, whereas G3 tumors demonstrated an approximately twofold increase in estriol concentration. Testosterone and cortisol levels were elevated in the mitochondria of all tumors by 1.6-fold and more than twofold, respectively. Progesterone content was increased by 2.3–3.8-fold in the mitochondria of G1–G2 tumors but decreased by 4.3–5.9-fold in comparison with the control mitochondria. The levels of androgen and estrogen receptors were elevated in the mitochondria of all tumors, whereas the ERα/ERβ ratio decreased by 1.7–3.6-fold. Progesterone receptor levels were increased in G1–G2 mitochondria only in patients with T2DM, whereas in G3 tumors they were elevated regardless of T2DM status. Type 2 diabetes mellitus was associated with cholesterol accumulation in the mitochondria of all tumors. Conclusion. Regardless of tumor differentiation grade and the presence of type 2 diabetes mellitus, endometrial adenocarcinoma mitochondria are characterized by increased levels of testosterone, cortisol, and sex hormone receptors, reflecting profound metabolic reprogramming of these organelles. Estradiol predominates in G1–G2 tumors, whereas estriol is the dominant estrogen in G3 tumors, which may contribute to increased tumor aggressiveness. Type 2 diabetes mellitus is associated with mitochondrial cholesterol accumulation, which may partly explain the more severe clinical course of endometrial adenocarcinoma in these patients.
- 23 June 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (2) , 34-46
Features of steroid hormone and receptor content in the mitochondria of endometrial adenocarcinoma according to tumor differentiation grade and the presence of type 2 diabetes mellitus
Mitochondria play a key role in cellular metabolism, steroid hormone synthesis, and the regulation of redox homeostasis. However, the role of mitochondrial steroidogenesis in the progression of endometrial adenocarcinoma (EA), particularly in the presence of type 2 diabetes mellitus (T2DM), remains poorly understood. Purpose of the study. To determine the concentrations of steroid hormones and their receptors in the mitochondrial fraction of G1–G3 endometrial adenocarcinoma tissue compared with intact endometrium and to evaluate the modifying effect of type 2 diabetes mellitus on these parameters. Patients and methods. Mitochondria were isolated by differential centrifugation from tumor tissue obtained from 92 patients with endometrial adenocarcinoma (G1–G3) and from morphologically normal endometrium (control group). Standard enzyme-linked immunosorbent assay (ELISA) kits were used to determine the concentrations of estradiol (E2), estriol (E3), estrone (E1) and their receptors (ERα, ERβ), testosterone (T) and the androgen receptor (AR), progesterone (P4) and the progesterone receptor (PR), as well as cortisol and cholesterol. Statistical analysis was performed using Statistica 10 software. Results. In the mitochondria of G1–G2 endometrial adenocarcinomas, the estradiol level was approximately twofold higher than in the control group, whereas G3 tumors demonstrated an approximately twofold increase in estriol concentration. Testosterone and cortisol levels were elevated in the mitochondria of all tumors by 1.6-fold and more than twofold, respectively. Progesterone content was increased by 2.3–3.8-fold in the mitochondria of G1–G2 tumors but decreased by 4.3–5.9-fold in comparison with the control mitochondria. The levels of androgen and estrogen receptors were elevated in the mitochondria of all tumors, whereas the ERα/ERβ ratio decreased by 1.7–3.6-fold. Progesterone receptor levels were increased in G1–G2 mitochondria only in patients with T2DM, whereas in G3 tumors they were elevated regardless of T2DM status. Type 2 diabetes mellitus was associated with cholesterol accumulation in the mitochondria of all tumors. Conclusion. Regardless of tumor differentiation grade and the presence of type 2 diabetes mellitus, endometrial adenocarcinoma mitochondria are characterized by increased levels of testosterone, cortisol, and sex hormone receptors, reflecting profound metabolic reprogramming of these organelles. Estradiol predominates in G1–G2 tumors, whereas estriol is the dominant estrogen in G3 tumors, which may contribute to increased tumor aggressiveness. Type 2 diabetes mellitus is associated with mitochondrial cholesterol accumulation, which may partly explain the more severe clinical course of endometrial adenocarcinoma in these patients.
- Open Access
- 20 March 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (1) , 31-43
Features of mitochondrial hormone and receptor levels in aggressive endometrial cancer subtypes
Serous endometrial carcinoma (SEC) and clear cell endometrial carcinoma (CCEC) are among the most aggressive subtypes of endometrial cancer (EC), characterized by a high risk of recurrence and metastasis. Mitochondria play a key role in steroidogenesis and cellular metabolism; however, their contribution to hormonal and metabolic tumor adaptation in rare forms of EC remains poorly understood. Purpose of the study . To comprehensively assess the levels of sex hormones, their receptors, cortisol, and glutathione in mitochondria isolated from SEC and CCEC tissues.Patients and methods. This prospective study included 41 patients with rare forms of EC. Mitochondria were isolated from tumor tissues – 21 SEC and 20 CCEC. The control group was composed of 20 samples of endometrium unaffected by tumour. Concentrations of estrone, estradiol, estriol, testosterone, progesterone, estrogen receptors (REα, REβ), androgen receptors, progesterone receptors (RP4), cortisol, cholesterol, and glutathione were determined by enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using Statistica 10.0 software. Results . In mitochondria obtained from SEC and CCEC, compared with tumor-free endometrial mitochondria, levels of testosterone and progesterone were increased by an average of 1.5‑fold, estriol by 1.8‑fold and 2.2‑fold, REβ by 3.5‑fold and 1.8‑fold, RP4 by 2.4‑fold and 5.2‑fold, and the REβ/REα ratio by 2.2‑fold and 1.9‑fold, respectively. Estradiol, REα, and androgen receptor levels exceeded control values only in SEC mitochondria, by 2.0‑fold, 1.8‑fold, and 2.2‑fold, respectively. Cortisol and cholesterol concentrations in mitochondria from rare endometrial cancer subtypes were 1.9–2.5‑fold higher than in tumor-free endometrial mitochondria, while glutathione levels were increased by 1.9–2.4‑fold. Conclusion . SEC and CCEC are characterized by the formation of a unique mitochondrial hormonal microenvironment with estriol predominance and a high REβ/REα ratio, which may mediate suppression of apoptosis and enhanced proliferation. Differences in receptor profiles indicate distinct mechanisms of hormonal signaling, potentially determining specific features of the clinical course of each tumor subtype. Accumulation of cholesterol and cortisol in the context of elevated glutathione levels indicates metabolic reprogramming aimed at sustaining steroidogenesis and resistance to oxidative stress and apoptosis.
- 20 March 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (1) , 31-43
Open AccessFeatures of mitochondrial hormone and receptor levels in aggressive endometrial cancer subtypes
Serous endometrial carcinoma (SEC) and clear cell endometrial carcinoma (CCEC) are among the most aggressive subtypes of endometrial cancer (EC), characterized by a high risk of recurrence and metastasis. Mitochondria play a key role in steroidogenesis and cellular metabolism; however, their contribution to hormonal and metabolic tumor adaptation in rare forms of EC remains poorly understood. Purpose of the study . To comprehensively assess the levels of sex hormones, their receptors, cortisol, and glutathione in mitochondria isolated from SEC and CCEC tissues.Patients and methods. This prospective study included 41 patients with rare forms of EC. Mitochondria were isolated from tumor tissues – 21 SEC and 20 CCEC. The control group was composed of 20 samples of endometrium unaffected by tumour. Concentrations of estrone, estradiol, estriol, testosterone, progesterone, estrogen receptors (REα, REβ), androgen receptors, progesterone receptors (RP4), cortisol, cholesterol, and glutathione were determined by enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using Statistica 10.0 software. Results . In mitochondria obtained from SEC and CCEC, compared with tumor-free endometrial mitochondria, levels of testosterone and progesterone were increased by an average of 1.5‑fold, estriol by 1.8‑fold and 2.2‑fold, REβ by 3.5‑fold and 1.8‑fold, RP4 by 2.4‑fold and 5.2‑fold, and the REβ/REα ratio by 2.2‑fold and 1.9‑fold, respectively. Estradiol, REα, and androgen receptor levels exceeded control values only in SEC mitochondria, by 2.0‑fold, 1.8‑fold, and 2.2‑fold, respectively. Cortisol and cholesterol concentrations in mitochondria from rare endometrial cancer subtypes were 1.9–2.5‑fold higher than in tumor-free endometrial mitochondria, while glutathione levels were increased by 1.9–2.4‑fold. Conclusion . SEC and CCEC are characterized by the formation of a unique mitochondrial hormonal microenvironment with estriol predominance and a high REβ/REα ratio, which may mediate suppression of apoptosis and enhanced proliferation. Differences in receptor profiles indicate distinct mechanisms of hormonal signaling, potentially determining specific features of the clinical course of each tumor subtype. Accumulation of cholesterol and cortisol in the context of elevated glutathione levels indicates metabolic reprogramming aimed at sustaining steroidogenesis and resistance to oxidative stress and apoptosis.
- Open Access
- 29 January 2026
- Published by Institute of Cytology and Genetics, SB RAS in Siberian Scientific Medical Journal
- Vol. 45 (6) , 147-159
Dendritic cell vaccines in immunotherapy of gynecological malignancies: current strategies and clinical perspectives
Immunotherapeutic vaccines are a promising direction in the treatment of oncological diseases. In recent years, significant progress has been made in understanding the mechanisms of interaction between the immune system and tumor cells and in developing strategies to overcome tumor immunosuppression. Aim of the study was to systematize modern data on the development and clinical use of dendritic cell (DC) vaccines for the treatment of gynecological cancer, evaluate their effectiveness, identify key limitations and promising strategies for enhancing the antitumor response. Material and methods. The PubMed, Google Scholar and eLIBRARY.RU databases were used to write the literature review. Results. Clinical studies demonstrate that DC vaccines are capable of inducing a specific antitumor immune response, increasing relapse-free and overall survival in patients with gynecological cancers. The greatest efficiency is observed in combination with chemotherapy, especially when using personalized vaccines based on autologous tumor lysates or neoantigens. However, limitations to their widespread use include response heterogeneity, manufacturing complexity, and the need to optimize the timing of administration relative to other treatments. Conclusions. DC vaccines represent a promising direction for immunotherapy of gynecologic malignancies, but require further research to overcome current limitations. The development of personalized approaches and combination strategies could significantly improve their clinical effectiveness.
- 29 January 2026
- Published by Institute of Cytology and Genetics, SB RAS in Siberian Scientific Medical Journal
- Vol. 45 (6) , 147-159
Open AccessDendritic cell vaccines in immunotherapy of gynecological malignancies: current strategies and clinical perspectives
Immunotherapeutic vaccines are a promising direction in the treatment of oncological diseases. In recent years, significant progress has been made in understanding the mechanisms of interaction between the immune system and tumor cells and in developing strategies to overcome tumor immunosuppression. Aim of the study was to systematize modern data on the development and clinical use of dendritic cell (DC) vaccines for the treatment of gynecological cancer, evaluate their effectiveness, identify key limitations and promising strategies for enhancing the antitumor response. Material and methods. The PubMed, Google Scholar and eLIBRARY.RU databases were used to write the literature review. Results. Clinical studies demonstrate that DC vaccines are capable of inducing a specific antitumor immune response, increasing relapse-free and overall survival in patients with gynecological cancers. The greatest efficiency is observed in combination with chemotherapy, especially when using personalized vaccines based on autologous tumor lysates or neoantigens. However, limitations to their widespread use include response heterogeneity, manufacturing complexity, and the need to optimize the timing of administration relative to other treatments. Conclusions. DC vaccines represent a promising direction for immunotherapy of gynecologic malignancies, but require further research to overcome current limitations. The development of personalized approaches and combination strategies could significantly improve their clinical effectiveness.
- 24 December 2025
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 15 (4)
Results of Transarterial Chemoembolization in Treatment of Primary and Metastatic Liver Cancer: Clinical Assessment
Introduction. Hepatocellular carcinoma is the third leading cause of cancer death worldwide with an extremely low five-year survival rate (20.3%) and colorectal cancer liver metastases accounting for significant 10–20% of all secondary tumors. Transarterial chemoembolization (TACE) represents a standard method of local palliative treatment; however, after the procedure, a stable hypoxic environment is formed contributing to aggressive relapses and further progression of the disease. The present study aims to assess the clinical efficacy and safety of TACE in patients with primary and metastatic liver cancer. Materials and methods. A retrospective analysis is conducted for 333 patients (181 men, 152 women) aged 19 to 83 years (mean age of 60.1 ± 0.55 years) treated at the National Medical Research Center for Oncology (Rostov-on-Don, Russian Federation). A total of 93 patients are diagnosed with hepatocellular carcinoma (ICD-10 C22.0); 240 have colorectal cancer metastases to the liver (ICD-10 C78.7). All underwent the TACE procedure. Two-year survival is analyzed using life tables, Kaplan-Meier method and Cox regression analysis to examine risk factors. Statistical analysis is performed using the Statistica 10 software. Results and discussion. During two years of observation, 61.9% of patients died; the overall survival rate is 38.1%. The highest risk of death was observed in the first two months after TACE, remaining high until the eighth month. A Kaplan-Meier analysis shows a significant reduction in survival after five months. Risk factors include disease stage, tumor morphology and patient gender: metastatic disease and male gender were associated with lower survival. Conclusion. Overall survival after TACE remains low, especially in the first months. The identified risk factors can be used for more accurate identification of high-risk groups to optimize combined therapy and develop more effective treatment strategies.
- 24 December 2025
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 15 (4)
Results of Transarterial Chemoembolization in Treatment of Primary and Metastatic Liver Cancer: Clinical Assessment
Introduction. Hepatocellular carcinoma is the third leading cause of cancer death worldwide with an extremely low five-year survival rate (20.3%) and colorectal cancer liver metastases accounting for significant 10–20% of all secondary tumors. Transarterial chemoembolization (TACE) represents a standard method of local palliative treatment; however, after the procedure, a stable hypoxic environment is formed contributing to aggressive relapses and further progression of the disease. The present study aims to assess the clinical efficacy and safety of TACE in patients with primary and metastatic liver cancer. Materials and methods. A retrospective analysis is conducted for 333 patients (181 men, 152 women) aged 19 to 83 years (mean age of 60.1 ± 0.55 years) treated at the National Medical Research Center for Oncology (Rostov-on-Don, Russian Federation). A total of 93 patients are diagnosed with hepatocellular carcinoma (ICD-10 C22.0); 240 have colorectal cancer metastases to the liver (ICD-10 C78.7). All underwent the TACE procedure. Two-year survival is analyzed using life tables, Kaplan-Meier method and Cox regression analysis to examine risk factors. Statistical analysis is performed using the Statistica 10 software. Results and discussion. During two years of observation, 61.9% of patients died; the overall survival rate is 38.1%. The highest risk of death was observed in the first two months after TACE, remaining high until the eighth month. A Kaplan-Meier analysis shows a significant reduction in survival after five months. Risk factors include disease stage, tumor morphology and patient gender: metastatic disease and male gender were associated with lower survival. Conclusion. Overall survival after TACE remains low, especially in the first months. The identified risk factors can be used for more accurate identification of high-risk groups to optimize combined therapy and develop more effective treatment strategies.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 59-74
Application of dendritic cell vaccine immunotherapy in gynecologic malignancies
The development of antitumor strategies aimed at restoring systemic and local immune regulation is considered one of the most promising directions. Technologies based on dendritic cell vaccines (DCVs), characterized by minimal toxicity and alignment with fundamental immunological mechanisms of antitumor resistance, are of particular interest. Purpose of the study . Is to evaluate the effectiveness of immunotherapeutic approaches for gynecologic malignancies using DCVs and to outline promising directions for further development. Materials and methods. A literature search was conducted in the bibliographic registers MEDLINE, ClinicalTrial.gov., eLIBRARY and CyberLeninka, using the search systems PubMed, Google Scholar. The vast majority of the identified sources are indexed in Scopus and Web of Science. The review includes more than 60 publications in Russian and English, over 50 % of which were published within the past five years. Results. The analysis summarizes data on the clinical outcomes of DCV-based therapy in advanced cervical cancer, endometrial cancer, and ovarian cancer. Reported beneficial effects include temporary disease stabilization, improved overall survival and quality of life in advanced malignancies, enhanced efficacy of subsequent chemotherapy, and occasional cases of partial or complete remission. The review also addresses potential reasons for the limited efficacy of DCVs, as well as possible combinations of this technology with other immunotherapeutic modalities and traditional anticancer treatments. The currently modest therapeutic effectiveness of DCVs in gynecologic cancers may be attributed both to the insufficient maturity of the technology and to inherent mechanisms of tumor immune evasion. Conclusion. The therapeutic potential of DCVs has not yet been fully realized. Advances in immunotherapy, molecular biology, nanotechnology, and strategies for activating systemic and local antitumor resistance mechanisms provide a foundation for defining future research priorities aimed at improving the efficacy of DCVs as an important component of multimodal treatment for gynecologic malignancies.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 59-74
Application of dendritic cell vaccine immunotherapy in gynecologic malignancies
The development of antitumor strategies aimed at restoring systemic and local immune regulation is considered one of the most promising directions. Technologies based on dendritic cell vaccines (DCVs), characterized by minimal toxicity and alignment with fundamental immunological mechanisms of antitumor resistance, are of particular interest. Purpose of the study . Is to evaluate the effectiveness of immunotherapeutic approaches for gynecologic malignancies using DCVs and to outline promising directions for further development. Materials and methods. A literature search was conducted in the bibliographic registers MEDLINE, ClinicalTrial.gov., eLIBRARY and CyberLeninka, using the search systems PubMed, Google Scholar. The vast majority of the identified sources are indexed in Scopus and Web of Science. The review includes more than 60 publications in Russian and English, over 50 % of which were published within the past five years. Results. The analysis summarizes data on the clinical outcomes of DCV-based therapy in advanced cervical cancer, endometrial cancer, and ovarian cancer. Reported beneficial effects include temporary disease stabilization, improved overall survival and quality of life in advanced malignancies, enhanced efficacy of subsequent chemotherapy, and occasional cases of partial or complete remission. The review also addresses potential reasons for the limited efficacy of DCVs, as well as possible combinations of this technology with other immunotherapeutic modalities and traditional anticancer treatments. The currently modest therapeutic effectiveness of DCVs in gynecologic cancers may be attributed both to the insufficient maturity of the technology and to inherent mechanisms of tumor immune evasion. Conclusion. The therapeutic potential of DCVs has not yet been fully realized. Advances in immunotherapy, molecular biology, nanotechnology, and strategies for activating systemic and local antitumor resistance mechanisms provide a foundation for defining future research priorities aimed at improving the efficacy of DCVs as an important component of multimodal treatment for gynecologic malignancies.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 6-15
The content of steroid hormones in the mitochondria of unchanged and tumor tissue of the uterine body
Mitochondria regulate a wide range of processes, including stress responses, metabolism, immunity, differentiation, redox homeostasis, and steroidogenesis, and also serve as the principal intracellular source of reactive oxygen species (ROS). Mitochondrial dysfunction has been linked to the development of various pathological conditions, including the growth of both benign and malignant tumors. Purpose of the study . Determination of the level of steroid hormones in the mitochondria of various tissues of the uterine body. Materials and methods . The study included 65 patients with benign and malignant diseases of the uterus: 25 patients with endometrioid adeno‑ carcinoma of the uterus (EAC) of low differentiation (G3) stage II–III; 15 patients with leiomyosarcoma of the uterus stage I–III; and 25 patients with uterine myoma. Mitochondria from native samples of uterine tumors were isolated by differential centrifugation in a high-speed refrigerated centrifuge Avanti J-E, Becman Coulter. For the comparison group, mitochondria were isolated from intact uterine tissue. The levels of estradiol (E2), testosterone (T), progesterone (P4), and cortisol were determined using standard ELISA kits (Monobind, USA) in mitochondria isolated from the indicated tissues. A statistical analysis of the results was conducted using the Statistica 10.0 software package. Results. Irrespective of the nature of the tumor process (benign or malignant), a decrease in the P4 level by 2.7 to 9.1 times, but an increase in the content of cortisol by 1.3 to 3.7 times and T by 2.1 to 3.7 times were detected in the mitochondria of uterine tumors. Conversely, the concentration of E2 in the mitochondria of uterine fibroids exhibited an increase of 2.2 times compared to the indicators in the mitochondria of the intact uterus. No significant differences were observed in the mitochondria of EAC, while a decrease of 1.4 times was noted in the mi‑ tochondria of uterine sarcoma. Conclusion . There is a change in the content of steroid hormones in In the mitochondria of uterine tumors, consisting in an increase in the concentrations of cortisol and testosterone and progesterone deficiency regardless of the type of pathology, but a relative or absolute defi‑ ciency of estrogens only in the mitochondria of malignant tumors. Changes in the steroid background of tumor mitochondria, compared with the mitochondria of the intact uterus, probably have a significant effect on both the energy balance of cells and the production of ROS, as well as on proliferative processes.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 6-15
The content of steroid hormones in the mitochondria of unchanged and tumor tissue of the uterine body
Mitochondria regulate a wide range of processes, including stress responses, metabolism, immunity, differentiation, redox homeostasis, and steroidogenesis, and also serve as the principal intracellular source of reactive oxygen species (ROS). Mitochondrial dysfunction has been linked to the development of various pathological conditions, including the growth of both benign and malignant tumors. Purpose of the study . Determination of the level of steroid hormones in the mitochondria of various tissues of the uterine body. Materials and methods . The study included 65 patients with benign and malignant diseases of the uterus: 25 patients with endometrioid adeno‑ carcinoma of the uterus (EAC) of low differentiation (G3) stage II–III; 15 patients with leiomyosarcoma of the uterus stage I–III; and 25 patients with uterine myoma. Mitochondria from native samples of uterine tumors were isolated by differential centrifugation in a high-speed refrigerated centrifuge Avanti J-E, Becman Coulter. For the comparison group, mitochondria were isolated from intact uterine tissue. The levels of estradiol (E2), testosterone (T), progesterone (P4), and cortisol were determined using standard ELISA kits (Monobind, USA) in mitochondria isolated from the indicated tissues. A statistical analysis of the results was conducted using the Statistica 10.0 software package. Results. Irrespective of the nature of the tumor process (benign or malignant), a decrease in the P4 level by 2.7 to 9.1 times, but an increase in the content of cortisol by 1.3 to 3.7 times and T by 2.1 to 3.7 times were detected in the mitochondria of uterine tumors. Conversely, the concentration of E2 in the mitochondria of uterine fibroids exhibited an increase of 2.2 times compared to the indicators in the mitochondria of the intact uterus. No significant differences were observed in the mitochondria of EAC, while a decrease of 1.4 times was noted in the mi‑ tochondria of uterine sarcoma. Conclusion . There is a change in the content of steroid hormones in In the mitochondria of uterine tumors, consisting in an increase in the concentrations of cortisol and testosterone and progesterone deficiency regardless of the type of pathology, but a relative or absolute defi‑ ciency of estrogens only in the mitochondria of malignant tumors. Changes in the steroid background of tumor mitochondria, compared with the mitochondria of the intact uterus, probably have a significant effect on both the energy balance of cells and the production of ROS, as well as on proliferative processes.
- Open Access
- 15 October 2025
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 24 (3) , 172-178
Dendritic cells as a basis for designing anti-cancer vaccines
Dendritic cells (DCs) have been shown to play a pivotal role in orchestrating the immune response against tumors, thereby acting as a link between innate and adaptive immunity. DCs capture, process, and present tumor antigens to T cells, which triggers a specific immune response aimed at destroying cancer cells. DCs are a heterogeneous population that includes several subtypes, such as conventional DCs (cDC1, cDC2) and plasmacytoid DCs (pDC). Each subtype has unique functions: cDC1s specialize in activating CD8+ T cells, while pDCs produce interferons in response to viral infections. In a tumor microenvironment, DCs are often depleted of their functionality due to immunosuppressive factors, such as IL-6 and PGE2, which impedes their ability to activate T cells. Furthermore, an imbalance between oxidative phosphorylation and glycolysis regulated by the AMPK/mTOR axis may lead to the immunosuppressive phenotype of DCs.A promising direction in cancer immunotherapy is the creation of DC-based vaccines that can restore the immunogenicity of cold tumors lacking T cell infiltration. Such vaccines can be created by generating DCs in vitro or modifying them to enhance the presentation of tumor antigens.Despite significant advances, the biology of DCs remains poorly understood. This lecture highlights the importance of DCs in developing new cancer treatment strategies and opens up prospects for more effective immunotherapeutic approaches.
- 15 October 2025
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 24 (3) , 172-178
Open AccessDendritic cells as a basis for designing anti-cancer vaccines
Dendritic cells (DCs) have been shown to play a pivotal role in orchestrating the immune response against tumors, thereby acting as a link between innate and adaptive immunity. DCs capture, process, and present tumor antigens to T cells, which triggers a specific immune response aimed at destroying cancer cells. DCs are a heterogeneous population that includes several subtypes, such as conventional DCs (cDC1, cDC2) and plasmacytoid DCs (pDC). Each subtype has unique functions: cDC1s specialize in activating CD8+ T cells, while pDCs produce interferons in response to viral infections. In a tumor microenvironment, DCs are often depleted of their functionality due to immunosuppressive factors, such as IL-6 and PGE2, which impedes their ability to activate T cells. Furthermore, an imbalance between oxidative phosphorylation and glycolysis regulated by the AMPK/mTOR axis may lead to the immunosuppressive phenotype of DCs.A promising direction in cancer immunotherapy is the creation of DC-based vaccines that can restore the immunogenicity of cold tumors lacking T cell infiltration. Such vaccines can be created by generating DCs in vitro or modifying them to enhance the presentation of tumor antigens.Despite significant advances, the biology of DCs remains poorly understood. This lecture highlights the importance of DCs in developing new cancer treatment strategies and opens up prospects for more effective immunotherapeutic approaches.
- 30 September 2025
- Published by Ulyanovsk State University in Ulyanovsk Medico-biological Journal
- No. 3
MODERN CONCEPTS FOR ANTITUMOR VACCINE DESIGN
Immunotherapeutic vaccines represent a promising strategy in oncology. Recently, significant progress has been made in understanding the mechanisms of interaction between the immune system and tumor cells and in developing strategies to overcome tumor immunosuppression. The aim of the review is to systematize modern data on approaches to the development of antitumor vaccines, analyze their mode of action, advantages and limitations. Materials and methods. The PubMed, Google Scholar and eLibrary.ru were used for literature review. Results. The review considers various platforms for creating antitumor vaccines: dendritic and tumor cells, nucleic acids, oncolytic viruses and peptides. Nucleic acid vaccines (DNA/mRNA) can encode multiple epitopes, including neoantigens, and are easily adapted for personalized therapy. Viral and cellular platforms combine direct tumor lysis with immunostimulation. Research papers present modern methods on modifying tumor cells to enhance their immunogenicity, such as adjuvant therapy, genetic engineering, and antigen delivery platforms. The review highlights the prospects for using exosomes and mitochondria as carriers for delivering therapeutic molecules, as well as combined approaches that include the use of vaccines in combination with immune checkpoint inhibitors, cytokine-induced killer cells and radiation therapy, which helps to overcome tumor resistance to immunotherapy and enhance antitumor immunity. The problems associated with antitumor vaccines in elderly patients are discussed. Conclusion. Modern antitumor vaccines show significant therapeutic potential, particularly in combination with other treatment modalities. Successful integration of vaccines into complex cancer therapy requires interdisciplinary collaboration and continued basic and clinical research. Further research should be aimed at optimizing combination therapy regimens, developing response biomarkers, and adapting vaccines for elderly patients.
- 30 September 2025
- Published by Ulyanovsk State University in Ulyanovsk Medico-biological Journal
- No. 3
MODERN CONCEPTS FOR ANTITUMOR VACCINE DESIGN
Immunotherapeutic vaccines represent a promising strategy in oncology. Recently, significant progress has been made in understanding the mechanisms of interaction between the immune system and tumor cells and in developing strategies to overcome tumor immunosuppression. The aim of the review is to systematize modern data on approaches to the development of antitumor vaccines, analyze their mode of action, advantages and limitations. Materials and methods. The PubMed, Google Scholar and eLibrary.ru were used for literature review. Results. The review considers various platforms for creating antitumor vaccines: dendritic and tumor cells, nucleic acids, oncolytic viruses and peptides. Nucleic acid vaccines (DNA/mRNA) can encode multiple epitopes, including neoantigens, and are easily adapted for personalized therapy. Viral and cellular platforms combine direct tumor lysis with immunostimulation. Research papers present modern methods on modifying tumor cells to enhance their immunogenicity, such as adjuvant therapy, genetic engineering, and antigen delivery platforms. The review highlights the prospects for using exosomes and mitochondria as carriers for delivering therapeutic molecules, as well as combined approaches that include the use of vaccines in combination with immune checkpoint inhibitors, cytokine-induced killer cells and radiation therapy, which helps to overcome tumor resistance to immunotherapy and enhance antitumor immunity. The problems associated with antitumor vaccines in elderly patients are discussed. Conclusion. Modern antitumor vaccines show significant therapeutic potential, particularly in combination with other treatment modalities. Successful integration of vaccines into complex cancer therapy requires interdisciplinary collaboration and continued basic and clinical research. Further research should be aimed at optimizing combination therapy regimens, developing response biomarkers, and adapting vaccines for elderly patients.